A Phase III Study Comparing Different Types of Surgery to Treat Patients with Stage IA Non-Small Cell Lung Cancer

Full Title

A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (Less than or equal to 2cm) Peripheral Non-Small Cell Lung Cancer (Alliance/CALGB 140503)

Purpose

There are different types of surgery used to treat early-stage lung cancer. These include lobectomy (removal of a lobe of the lung), wedge resection (removal of a small section of a lobe containing tumor tissue), and segmentectomy (removal of a segment or subdivision of a lobe). Wedge resection or segmentectomy (types of “sublobar resection”) may be less invasive than lobectomy for treating non-small cell lung cancer (NSCLC), and may have fewer side effects and improve recovery. It is not yet known, however, how the effectiveness of sublobar resection compares with lobectomy for treating patients with early (stage IA) NSCLC.

In this study, researchers are comparing the effectiveness of sublobar resection versus lobectomy in patients with stage IA NSCLC. Patients will be randomly assigned to have either a sublobar resection (wedge resection or segmentectomy) or lobectomy. They will be monitored every six months for two years after surgery, and then annually for five years.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage IA NSCLC (a tumor size 2 cm or less and no evidence of spread beyond the lung).
  • Patients’ cancers must be operable.
  • Patients may not have previously received chemotherapy or radiation therapy for their NSCLC.
  • Patients may not have had another cancer in the three years preceding the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. James Huang at 646-888-3055.

Protocol

14-182

Phase

III

Disease Status

Newly Diagnosed

Investigator

Co-Investigators